Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Polycythemia Vera 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Osteosarcoma 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Hepatocellular 1

Interventions

Imatinib Mesylate 10Peripheral Blood Stem Cell Transplantation 8Hydroxyurea 7Interferon-alpha 6Cytarabine 6Radiotherapy 4Filgrastim 4Dasatinib 4Cyclosporine 4Cyclophosphamide 4Busulfan 4nilotinib 3Methotrexate 3Idarubicin 3Early Intervention, Educational 3olverembatinib 2liposomal amphotericin B 2Therapeutics 2Psychiatric Rehabilitation 2Mycophenolic Acid 2Etoposide 2Cyclosporins 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2sargramostim 1ponatinib 1peginterferon alfa-2b 1fludarabine phosphate 1bosutinib 1asciminib 1Whole-Body Irradiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myeloid, Chronic-Phase × peginterferon alfa-2b × Clear all
NCT00050531 2016-05-11

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

M.D. Anderson Cancer Center

Phase 3 Completed
94 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡